Cellectis Reports 100.3M Shares, 89.4M Voting Rights as of June 30, 2025

Cellectis, a biotechnology firm listed on the Euronext Growth market, has released its monthly report on share capital and voting rights as of June 30, 2025. The company disclosed a total of 100,325,229 shares and 89,428,630 voting rights, in compliance with French financial regulations. Investors can contact Arthur Stril, the Chief Financial Officer & Chief Business Officer, for further information.